A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells
Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Noemı́ Reguart et al. · Journal of Thoracic Oncology · 2008
Cited by 114 works. doi:10.1097/jto.0b013e318189f579
Authors
- Miguel Ángel Molina‐Vila
- Jordi Bertrán-Alamillo
- Noemı́ Reguart
- Miquel Tarón
- Eva Castellà
- Mariona Llatjós
- Carlota Costa
- Clara Mayo
- Anna Pradas
- Cristina Queralt
- Mónica Botia
- María Pérez-Cano
- Esther Carrasco
- Mireia Tomàs
- José Luís Mate
- Teresa Morán
- Rafael Rosell
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
- Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence
- Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
- Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
- Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants